Use of a Smartphone Application on the Detection of Complications Related to Smoking
Use of a Smartphone Application on the Detection of Complications Related to Smoking
Smokers do not know the symptoms of cancer and wait on average 5 months with symptoms before
 consulting. 80% of lung cancers are diagnosed at too late and incurable stage.

 Systematic CT screening of smokers is under evaluation and currently not supported because
 expensive and little used in real life (in the US 1.8% of smokers after 7 years of
 establishment in the USA).

 An English study showed an increase in the number of operable stage cancers of 3% among
 smokers by calling them on a trailing cough by a simple poster campaign ("You smoke, you
 cough for more than 3 weeks, consult").

 Regarding COPD, it is linked to tobacco in 85% of cases, affects 3.5 million French and is in
 2013 the 4th leading cause of death in France. The evolution of COPD is marked by
 exacerbations, period of acute aggravation of symptoms, responsible for the deterioration of
 the quality of life or even hospitalization or death. COPD remains a silent killer
 responsible, according to this same summary review, of 16,500 deaths per year in France.

 Dr DENIS has developed a web application that has shown a 7-month survival benefit by early
 detection of lung cancer relapses based on the reporting of patient symptoms analyzed by a
 validated algorithm in 300 patients and 1 randomized trial.

 The Applitabac app takes this concept of symptom self-assessment by patients. By multiplying
 the number of symptoms analyzed compared to the English study, Applitabac should be able to
 increase the sensitivity of this early detection of COPD and increase the number of operable
 bronchial cancers and increase the chances of survival of patients.
Inclusion Criteria:

 -  Age >= 18 years old

 -  Applitabac user who has received a notification directing him to his doctor

 -  Smoker or former smoker (current smoking cessation or ≤ 5 years)

 -  Patient informed of the use of his data and not opposing it

 Exclusion Criteria:

 -  Presence of another evolutionary neoplasia in the past 2 years

 -  Patient who did not use the Applitabac app